Michael F MacLean
CIK 1383731 · Chief Financial Officer · last filed 2026-04-03
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
RNA price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
10578 SCIENCE CENTER DRIVE, SUITE 125
SAN DIEGO, CA 92121
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CAMP | Director | — | $3.21 | — | $0 | 1 | 2026-04-03 |
| Avidity Biosciences, Inc. (RNAM) Delisted | Chief Financial Officer | 0 | — | — | $0 | 1 | 2026-02-27 |
| RNA | Chief Financial Officer | 62,025 | $8.05 | $499.3K | -$15.13M | 18 | 2026-01-23 |
| Verve Therapeutics, Inc. (VERV) Delisted | Director | — | $11.13 | — | $0 | 7 | 2025-07-28 |
| AKCEA THERAPEUTICS, INC. (AKCA) Delisted | Chief Financial Officer | 48,000 | — | — | $0 | 6 | 2020-01-16 |
| BIIB | SVP, Chief Accounting Officer | 10,681 | $252.26 | $2.69M | -$1.52M | 21 | 2010-10-04 |
Recent Filings · Page 2 of 6
59 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-01-08 | RNA | Grant (A) | +25,000 | $0 | EDGAR |
| 2024-12-19 | RNA | Sell (S) | −11,151 | -$364.2K | EDGAR |
| 2024-11-08 | RNA | Mixed | −27,262 | -$4.18M | EDGAR |
| 2024-11-06 | Avidity Biosciences, Inc. (RNAM) Delisted | Notice (144) | −106,319 | -$4.79M | EDGAR |
| 2024-09-23 | RNA | Mixed | +38,490 | -$506.4K | EDGAR |
| 2024-06-28 | Verve Therapeutics, Inc. (VERV) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-06-20 | RNA | Mixed | +38,772 | -$439.3K | EDGAR |
| 2024-06-14 | RNA | Mixed | — | -$2.80M | EDGAR |
| 2024-06-12 | Avidity Biosciences, Inc. (RNAM) Delisted | Notice (144) | −104,245 | -$3.01M | EDGAR |
| 2024-05-16 | RNA | Mixed | — | -$1.46M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.